Torgeir Vaage

Torgeir Vaage Email and Phone Number

Cfo At Acesion Pharma @ Pluvia Biotech

Torgeir Vaage's Contact Details

Torgeir Vaage work email

Torgeir Vaage personal email

Torgeir Vaage's Current Company Details

Pluvia Biotech

Cfo At Acesion Pharma

Torgeir Vaage Work Experience Details

  • Chief Financial Officer
    Pluvia Biotech Sep 2023 - Present
    Bergen, No
  • Chief Financial Officer
    Teitur Trophics Jun 2023 - Present
    Aarhus, Dk
  • Chief Financial Officer
    Acesion Pharma Nov 2018 - Present
    Copenhagen, Capital Region, Dk
  • Chief Financial Officer
    Initiator Pharma Sep 2016 - Present
    Copenhagen, Capital Region Of Denmark, Dk
  • Chief Financial Officer
    Aqilion Ab May 2019 - Nov 2023
    Helsingborg, Skane County, Se
  • Cfo
    Adenium Biotech Aps Feb 2015 - Dec 2022
  • Coo
    Volusense Nov 2014 - Dec 2022
  • Board Member
    Mentis Cura Ehf Nov 2014 - Dec 2022
  • Ceo
    C10 Pharma Apr 2011 - Dec 2022
    Founder and CEO of C10 Pharma, a Norwegian biotech company focusing on developing effective and safe antibiotics to treat potentially life threatening diseases increasingly resistant to existing antibiotics. Our development program is based on a unique chemistry technology, enabling us to build unique properties - antimicrobial and ADMET - into a well characterized scaffold.The company is backed by Novo Seed and Sarsia Seed as well as grants from the Norwegian Research Council. We use a highly virtual business model, cooperating with specialist partners in chemistry and biology in Italy, India and US.Our Board of Directors is highly international and brings the company a strong set of capabilities within drug development and business development.
  • Ceo
    Geneseque As Aug 2012 - Aug 2014
  • Ceo
    Hepmarin As Feb 2011 - Dec 2011
    HepMarin is dedicated to developing anticoagulant medicine from biological material from the aquaculture industry. Heparin, the cornerstone anticoagulant therapy - both prophylactically and therapeutically - is extracted from pig intestines. This source of biological material has a number of shortcomings, notably traceability and controllability of the supply chain back to the starting material. Our company is developing heparins from salmon biomass, offering a highly traceable and controllable supply chain. The company is supported by Norsk Innovasjonskapital and Sarsia Seed, as well as through grants from the Norwegian Research Council.
  • Cfo
    Santosolve As Nov 2005 - Oct 2011
    Adelaide, South Australia, Au
  • Cfo
    C10 Pharma 2009 - 2010
  • Director
    Kikadini Villas 2005 - 2010
  • Partner
    Abg Sundal Collier Jun 1988 - Jun 2004
    Oslo, No
    Financial analyst
  • Senior Analyst
    Handelsbanken Capital Markets Jun 1997 - Jun 1998
    Stockholm, Stockholms Län, Se
    Financial analyst
  • Senior Analyst
    Norden Investment Banking Apr 1995 - Jun 1997
    Financial analyst
  • Senior Consultant
    At Kearney Aug 1993 - Apr 1995
    Senior consultant

Torgeir Vaage Education Details

  • University Of California, Berkeley, Haas School Of Business
    Business Administration
  • Norwegian School Of Economics (Nhh)
    Economics
  • Oppegård Videregående

Frequently Asked Questions about Torgeir Vaage

What company does Torgeir Vaage work for?

Torgeir Vaage works for Pluvia Biotech

What is Torgeir Vaage's role in his/her workplace?

Torgeir Vaage's role in his/her workplace is Cfo At Acesion Pharma.

What is Torgeir Vaage's email address?

Torgeir Vaage's email address is to****@****ail.com

What is Torgeir Vaage's role in his/her workplace?

Torgeir Vaage has skills like Biotechnology, Business Strategy, Business Development, Drug Development, Regulatory Affairs, and Chemistry.

Who are the industry peers of Torgeir Vaage at other companies?

Torgeir Vaage's peers at other companies are Kenneth Ahrend Petersen, Mai-Britt Zocca, Mårten Faret, Ulrik Sørensen, Breian Knudsen, and John Bell. and Mohamed Adhil. Torgeir Vaage's peers at other companies are Kenneth Ahrend Petersen, Mai-Britt Zocca, Mårten Faret, Ulrik Sørensen, Breian Knudsen, and John Bell. and Mohamed Adhil.